Because safety and cost issues will be the major limiting factors to refrain from using CAC score as a widespread screening test for cardiovascular diseases in low risk populations [13], our results point to serum anti-apoA-1 IgG as a promising cardiovascular risk stratification tool candidate in obese patients, as suggested earlier [19–21]. Here, APOA1 is linked to cardiovascular disorder.